Fatty liver disease (MASLD/MASH) trials in Saudi Arabia

5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  Where

  Riyadh

  Age

  18 years and over

  People

  1,800 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06632444 · EU 2024-513739-25-00
• Phase 3Taking people
  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  Where

  Riyadh

  Age

  18 years and over

  People

  1,590 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06632457 · EU 2024-513741-36-00
• Phase 3Taking people
  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  Where

  Riyadh

  Age

  18 years to 75 years

  People

  1,250 worldwide

  Run by

  GlaxoSmithKline

  See details and how to joinNCT07221188 · EU 2025-523674-16-00
• Phase 3Taking people
  A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

  Where

  Riyadh

  Age

  18 years to 75 years

  People

  1,200 worldwide

  Run by

  GlaxoSmithKline

  See details and how to joinNCT07221227
• No phaseTaking people
  Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes Mellitus

  Where

  Riyadh

  Age

  18 years to 60 years

  People

  1,000

  Run by

  King Saud University

  See details and how to joinNCT05697991